摘要
目的探究全胸腔镜下行肺叶切除术治疗早期非小细胞肺癌的疗效。方法回顾性选取单县中心医院于2021年1月—2023年1月收治的76例早期非小细胞肺癌患者的临床资料,按照手术的方法分为研究组和对照组,各38例。研究组实施全胸腔镜肺叶切除术治疗,对照组实施常规开胸肺叶切除术治疗,对比两组治疗疗效、手术时间、术中失血量、引流管留置时间、住院时间和并发症发生率。结果研究组的治疗有效率为94.73%,高于对照组的78.95%,差异有统计学意义(χ^(2)=4.146,P=0.042);研究组的手术时间、术中失血量、引流管留置时间、住院时间优于对照组,差异有统计学意义(P均<0.05);研究组的并发症发生率为2.63%,低于对照组的15.79%,差异有统计学意义(P<0.05)。结论对于早期非小细胞肺癌患者采用全胸腔镜肺叶切除术,能够有效提升治疗疗效、改善患者疼痛情况。
Objective To explore the efficacy of total thoracoscopic lobectomy in the treatment of early non-small cell lung cancer.Methods Clinical data of 76 patients with early non-small cell lung cancer admitted to Shanxian Central Hospital from January 2021 to January 2023 were retrospectively selected and divided into study group and control group according to surgical methods,with 38 cases in each group.Total thoracoscopic lobectomy was performed in the study group,while routine thoracotomy was performed in the control group.The therapeutic effect,operation time,intraoperative blood loss,drainage tube retention time,hospital stay and complication rate of the two groups were compared.Results The effective rate of the study group was 94.73%,higher than that of the control group(78.95%),and the difference was statistically significant(χ^(2)=4.146,P=0.042).The operation time,intraoperative blood loss,drainage tube retention time and hospital stay of the study group were better than those of the control group,and the differences were statistically significant(all P<0.05).The complication rate of the study group was 2.63%,lower than that of the control group(15.79%),and the difference was statistically significant(P<0.05).Conclusion For patients with early non-small cell lung cancer,total thoracoscopic lobectomy can effectively improve the therapeutic effect and improve the pain of patients.
作者
安术祥
周斌
王家富
AN Shuxiang;ZHOU Bin;WANG Jiafu(Department of Thoracic Surgery,Shanxian Central Hospital,Heze,Shandong Province,274300 China)
出处
《系统医学》
2024年第9期124-126,130,共4页
Systems Medicine
关键词
全胸腔镜
肺叶切除术
早期
非小细胞肺癌
Total thoracoscope
Pulmonary lobectomy
Early stage
Non-small cell lung cancer
